DOTA-NHS-ester TFA
Based on 2 publication(s) in Google Scholar
DOTA-NHS-ester TFA is a bifunctional reagent containing a DOTA chelating group and an NHS ester. DOTA-NHS-ester TFA can be conjugated to proteins/antibodies/HSA via primary amino groups for radiolabeling with radiometals, and when combined with 16-amino-1-hexadecanethiol hydrochloride, it enables the construction of self-assembled monolayers on gold surfaces for lectin microarrays. DOTA-NHS-ester TFA can be used to prepare DOTA-HSA-Z (HER2:342) imaging probes, as well as to construct Trop2-targeted radiotherapeutic and diagnostic probes for pancreatic cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 95.0%
- Formule: C22H32F3N5O12
- Masse moléculaire:615.51
-
Stockage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) DOTA-NHS-ester TFA
More
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
Activité biologique
Description
In Vitro
DOTA-NHS ester (3.78 mg; 2 h) TFA successfully conjugates to HSA, yielding a DOTA-HSA bioconjugate with approximately two DOTA molecules per HSA molecule[1].
DOTA-NHS-ester (10 mM; overnight) TFA in combination with 16-amino-1-hexadecanethiol hydrochloride successfully modifies gold chip surfaces, producing a rough surface topography and characteristic infrared absorption peaks consistent with covalent coupling of the reagent[2].
DOTA-NHS-ester (5-20 mM; 2 h) TFA modification concentration on gold biochips positively correlates with IgG protein binding capacity, with 10 mM selected as the optimal working concentration balancing performance and reagent efficiency[2].
DOTA-NHS-ester (10 mM; overnight) TFA modification of gold biochips proceeds effectively at both 25 °C and 37 °C, with 25 °C selected as the optimal working temperature for practical convenience[2].
DOTA-NHS-ester (10 mM; overnight) TFA modified gold biochips support specific, concentration-dependent binding of ConA lectin and its corresponding antibody, validating the platform's suitability for lectin-based assays[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Masse moléculaire 615.51
-
Formule C22H32F3N5O12
-
Color White to off-white
-
SMILES
OC(C(F)(F)F)=O.O=C(ON1C(CCC1=O)=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
-
DOTA-NHS-ester TFA purchased from MedChemExpress. Usage Cited in: Adv Nanobiomed Res. 2023 Sep 3.
PSP–NH2 was incubated with DOTA–NHS–ester for 1 h and conjugated with mPEG–NHS. Then, the particles were mixed with 64Cu (OAc)2 at 50 ℃ for 1 h to obtain the 64Cu-labelled PSP. PSP@Ab@PEG exhibited increased blood circulation in BALB/c mice with blood clearance half-life periods found to be 12 min.
DOTA-NHS-ester TFA purchased from MedChemExpress. Usage Cited in: Adv Nanobiomed Res. 2023 Sep 3.
PSP–NH2 was incubated with DOTA–NHS–ester for 1 h and conjugated with mPEG–NHS. Then, the particles were mixed with 64Cu (OAc)2 at 50 ℃ for 1 h to obtain the 64Cu-labelled PSP. More PSP–NH2 accumulated in the liver site while a lot more PSP@Ab@PEG accumulated in the spleen.
Solvant et solubilité
In Vitro:
DMSO : 125 mg/mL (203.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Hoppmann S, et al. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting. Bioconjugate chemistry. 2011 Mar 16;22(3):413-21. [Content Brief]
[3]. Li C, et al. Theranostic application of Cu/Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models. European journal of nuclear medicine and molecular imaging. 2022 Dec;50(1):168-183. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6247 mL | 8.1233 mL | 16.2467 mL | 40.6167 mL |
| 5 mM | 0.3249 mL | 1.6247 mL | 3.2493 mL | 8.1233 mL | |
| 10 mM | 0.1625 mL | 0.8123 mL | 1.6247 mL | 4.0617 mL | |
| 15 mM | 0.1083 mL | 0.5416 mL | 1.0831 mL | 2.7078 mL | |
| 20 mM | 0.0812 mL | 0.4062 mL | 0.8123 mL | 2.0308 mL | |
| 25 mM | 0.0650 mL | 0.3249 mL | 0.6499 mL | 1.6247 mL | |
| 30 mM | 0.0542 mL | 0.2708 mL | 0.5416 mL | 1.3539 mL | |
| 40 mM | 0.0406 mL | 0.2031 mL | 0.4062 mL | 1.0154 mL | |
| 50 mM | 0.0325 mL | 0.1625 mL | 0.3249 mL | 0.8123 mL | |
| 60 mM | 0.0271 mL | 0.1354 mL | 0.2708 mL | 0.6769 mL | |
| 80 mM | 0.0203 mL | 0.1015 mL | 0.2031 mL | 0.5077 mL | |
| 100 mM | 0.0162 mL | 0.0812 mL | 0.1625 mL | 0.4062 mL |
DOTA-NHS-ester TFA Related Classifications
HY-128890B Related Classifications
Powered by Bioz